Nordic Nanovector ASA: First Quarter 2016 Results Presentation and Webcast
Nordic Nanovector ASA (OSE:NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in
haematology and oncology, will announce its first quarter 2016 results on Thursday, 19 May 2016.
A presentation by Nordic Nanovector’s senior management team will take place at 8:30 am CEST at:
Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
Meeting Room: NYLAND
The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investor Relations/Webcast.
The results report and the presentation will be available at www.nordicnanovector.com in the section:
Investor Relations/Reports and Presentation/Quarterly Reports/2016 from 7:00 am CEST the same day.
###
About Nordic Nanovector:
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in
haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of
Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin
Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing
market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity
radionuclide (lutetium- 177). It has shown promising efficacy and a favourable safety profile in an ongoing Phase 1/2 study in a
difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL
with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications. Further
information about the Company can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
Nordic Nanovector ASA
Luigi Costa, Chief Executive Officer
Cell: +41 79 124 8601
Email: ir@nordicnanovector.com
or
Tone Kvåle, Chief Financial Officer
Cell: +47 91 51 95 76
Email: ir@nordicnanovector.com
or
Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44 207 282 2948/+44 207 282 2949
mark.swallow@citigatedr.co.uk / david.dible@citigatedr.co.uk
View source version on businesswire.com: http://www.businesswire.com/news/home/20160512005460/en/